Resverlogix (TSX:RVX) EBIT per Share : C$-0.04 (TTM As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Resverlogix EBIT per Share?

Resverlogix's EBIT per Share for the three months ended in Mar. 2024 was C$0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.04.

During the past 3 years, the average EBIT per Share Growth Rate was 39.90% per year. During the past 5 years, the average EBIT per Share Growth Rate was 39.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Resverlogix's EBIT per Share or its related term are showing as below:

TSX:RVX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -85.5 Med: -2.8 Max: 39.9
Current: 39.9

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Resverlogix was 39.90% per year. The lowest was -85.50% per year. And the median was -2.80% per year.

TSX:RVX's 3-Year EBIT Growth Rate is ranked better than
88.32% of 1301 companies
in the Biotechnology industry
Industry Median: 3.4 vs TSX:RVX: 39.90

Resverlogix's EBIT for the three months ended in Mar. 2024 was C$2.69 Mil.

Resverlogix EBIT per Share Historical Data

The historical data trend for Resverlogix's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix EBIT per Share Chart

Resverlogix Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.28

0.77

-0.13

-0.01

-0.07

Resverlogix Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.03	-0.02	-0.02	-0.01	0.01

Resverlogix EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Resverlogix's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-19.984	/	269.958
=	-0.07

Resverlogix's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	2.69	/	442.853
=	0.01

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.04

Resverlogix (TSX:RVX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Resverlogix EBIT per Share Related Terms

Thank you for viewing the detailed overview of Resverlogix's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Resverlogix (TSX:RVX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

RVXCF:USA RFS:Germany

Address

4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1

Website

https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Executives

Aaron Bradley Cann

Senior Officer

Resverlogix (TSX:RVX) Headlines

No Headlines